



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 49/04, 49/00	A1	(11) International Publication Number: WO 91/14460 (43) International Publication Date: 3 October 1991 (03.10.91)
(21) International Application Number: PCT/EP91/00587 (22) International Filing Date: 27 March 1991 (27.03.91) (30) Priority data: 9006977.4 28 March 1990 (28.03.90) GB (71) Applicant (for GB only): COCKBAIN, Julian, Roderick, Michaelson [GB/GB]; 27 Ladbroke Road, London W11 3PD (GB). (71) Applicant (for all designated States except US): NYCOMED AS [NO/NO]; Nycoveien 1-2, N-0401 Oslo 4 (NO). (72) Inventors; and (75) Inventors/Applicants (for US only) : BERG, Arne [NO/NO]; Stasjonsveien 37D, N-1310 Blommenholm (NO). ALMÉN, Torsten [SE/SE]; Ynglingegatan 7B, S-217 74 Malmö (SE). KRAUTWURST, Klaus, Dieter [DE/NO]; Trudvangveien 35C, N-1320 Stabekk (NO). KIM, Sook-Hui [KR/US]; 2680 Fayette Drive, No. 106, Mountain View, CA 94040 (US). RONGVED, Pål [NO/NO]; Hovdensvei 11, N-1457 Hellvik (NO). KLAVENESS, Jo [NO/NO]; Skøyen Terrasse 15, N-0276 Oslo 2 (NO). DUGSTAD, Harald [NO/NO]; Tore Hunds vei 6, N-0576 Oslo 5 (NO).		(74) Agents: COCKBAIN, Julian et al.; Frank B. Dehn & Co, Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CONTRAST MEDIA (57) Abstract The invention relates to the use as contrast enhancing agents in medical imaging, especially X-ray imaging, of multinuclear complexes, i.e. complexes, such as those of $W_2O_2(\mu_2O)_2$, in which the complexed entity comprises at least two contrast enhancing atoms.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TC	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

CONTRAST MEDIA

The present invention relates to the use in diagnostic imaging, in particular X-ray, ultrasound and scintigraphy of contrast agents comprising complexes of multinuclear moieties, and to contrast media containing such complexes.

All diagnostic imaging is based on the achievement of different signal levels from different structures within the body. Thus in X-ray imaging for example, for a given body structure to be visible in the image, the X-ray attenuation by that structure must differ from that of the surrounding tissues. The difference in signal between the body structure and its surroundings is frequently termed contrast and much effort has been devoted to means of enhancing contrast in diagnostic imaging since the greater the contrast between a body structure and its surroundings the higher the quality of the images and the greater their value to the physician performing the diagnosis. Moreover, the greater the contrast the smaller the body structures that may be visualized in the imaging procedure, i.e. increased contrast can lead to increased spatial resolution.

The diagnostic quality of images is strongly dependent on the inherent noise level in the imaging procedure - and the ratio of the contrast level to the noise level can thus be seen to represent an effective diagnostic quality factor for diagnostic images.

Achieving improvement in such a diagnostic quality factor has long been and still remains an important goal. In techniques such as X-ray and ultrasound, one approach to improving the diagnostic quality factor has been to introduce contrast enhancing materials, contrast agents, into the body region being imaged.

Thus in X-ray for example early examples of contrast agents were insoluble inorganic barium salts

which enhanced X-ray attenuation in the body zones into which they distributed. More recently the field of X-ray contrast agents has been dominated by soluble iodine containing compounds such as those marketed by Nycomed AS under the trade names Omnipaque and Amipaque.

Much recent work on X-ray contrast agents has concentrated on aminopolycarboxylic acid (APCA) chelates of heavy metal ions and, recognising that effective imaging of many body sites requires localization at the body sites in question of relatively high concentrations of the metal ions, there have been suggestions that polychelants, that is substances possessing more than one separate chelant moiety, might be used to achieve this.

However we have now found that contrast enhancement may be achieved particularly effectively by the use of multinuclear complexes, that is complexes wherein the complexed moiety itself comprises two or more contrast enhancing atoms or for X-ray or ultrasound two or more heavy atoms.

For the sake of clarity, the word "atom" is used to refer to ionic and covalently bonded forms and not simply to isolated uncharged atoms. Moreover it will be understood that the complexed moiety, while it is polynuclear, is not so large as to be considered to be a particle itself. Thus it will generally have maximum dimensions of 80Å or less, especially 40Å or less.

Thus viewed from one aspect the invention provides a method of generating an image of a human or non-human animal, preferably mammalian, body which method comprises administering to said body a physiologically tolerable contrast enhancing amount of a multinuclear complex and generating an image of at least part of said body, e.g. by X-ray, ultrasound, or scintigraphy.

Viewed from a further aspect the invention also provides a multinuclear complex, especially a tungsten and/or molybdenum complex, for use as a diagnostic image

contrast enhancing agent.

Viewed from a still further aspect the invention also provides a diagnostic imaging contrast medium comprising a multinuclear complex together with at least one sterile pharmaceutical carrier or excipient.

Viewed from another aspect the invention provides the use of a multinuclear complex for the manufacture of a contrast medium for use in imaging of the human or non-human animal body.

Multinuclear complexes have particular potential as contrast agents since, relative to mononuclear complexes such as the paramagnetic metal ion APCA chelates and polychelates conventionally proposed for use as X-ray contrast agents, the increase in the contrast enhancing atom content of the molecule is achieved with relatively little increase in the volume occupied by the contrast agent complexes, that is to say the use of multinuclear complexes enables a high ratio of contrast enhancing atom to overall complex volume to be achieved. Thus by increasing the relative content of contrast enhancing atoms in this way the total quantity of the contrast agent necessary in order to achieve the same contrast effect may be reduced and thus problems associated with contrast agent solubility or toxicity or with contrast medium viscosity may also be reduced.

The multinuclear complex used according to the invention may be ionic or, more preferably, may carry no net charge; most preferably the complex is non-ionic. Moreover it may be water-soluble or, less preferably, water-insoluble. Any necessary counterions should of course most preferably also be physiologically tolerable.

The range of physiologically acceptable counterions for therapeutically active agents is of course well known to pharmacologists.

Suitable counter cations include for example alkali and alkaline earth metal ions, e.g. sodium, calcium and

magnesium and zinc, ammonium and organic amine cations, e.g. meglumine, alkylammonium, polyhydroxyalkylammonium, basic protonated amino acids, etc. Suitable counteranions include for example halide (e.g. chloride, bromide or iodide), sulphate, mesylate, phosphate, etc.

As mentioned above, by multinuclear it is meant that the complexed moiety should comprise two or more contrast enhancing atoms (preferably in the form of a molecular ion or ion groups). The multinuclear moiety may thus optionally contain further atoms which may have little or no contrast enhancing effect but which may for example function as bridging atoms bonding the contrast enhancing atoms together. Particularly suitable examples of bridging atoms include those of group VIb, e.g. oxygen, sulphur, selenium and tellurium, and substituted nitrogen atoms. The use of selenium and tellurium, e.g. as bridging atoms, is especially attractive since the X-ray cross sections of these atoms, especially tellurium, are greater than those of the lower atomic weight sulphur, oxygen and nitrogen accordingly such atoms will contribute substantially to the overall X-ray attenuation by the complex.

Preferably the complexed multinuclear moiety will contain at least 2, for example up to 30, such as 2-15, e.g. 2 to 6, preferably 2 to 5 contrast enhancing atoms, particularly preferably 2, 3 or 4. The appropriate nature, e.g. the element, the isotope or the oxidation state, of the contrast enhancing atoms is of course dependent on the imaging technique in which the multinuclear complex is intended to function as a contrast agent. Thus for X-ray and ultrasound imaging the contrast enhancing atoms conveniently have atomic numbers of at least 37, preferably at least 50, and for scintigraphy the contrast enhancing atoms will be radioactive isotopes, e.g. radioactive metal ions.

For use as an X-ray contrast agent, it will generally be preferred that the multinuclear moiety

should contain two or more heavy metal atoms, e.g. lanthanide, transition metal or other metal atoms such as for example Ce, Hg, Sr, Y, Zr, Tc, Ru, In, Ta, Nb, Dy, Hf, W, Mo, Re, Os, Pb, Ba, Bi, Ga, Sn and Tl, however Mo and W are particularly preferred. The choice of heavy metal used in the multinuclear complexes will be determined by a variety of factors including the toxicity of the overall complex and the X-ray absorption characteristics of the heavy atom. In this regard it should be noted that while the X-ray absorption cross section for atoms generally increases with increasing atomic number, the absorption cross section is itself dependent on the X-ray wavelength and increases with increasing photon energy until slightly above a value termed the K-edge whereafter attenuation decreases. Thus there are photon energy ranges for which one element is a better X-ray attenuator than a second even though outside these ranges the second element may be the better attenuator. Consequently the multinuclear complexes according to the invention will each have optimum photon energy ranges making them particularly suitable for operation with X-ray imaging apparatus utilizing X-rays having such photon energy ranges. However, by choosing multinuclear complexes containing atoms of more than one heavy element one may create X-ray contrast agents having optimal performance in more than one photon energy band or over a broader band. The complexes used according to the present invention are thus particularly attractive since they can be selected so as to match their X-ray attenuation profiles with the X-ray emission profiles of particular X-ray sources - in effect the invention provides "tunable" X-ray contrast media.

Non-chelant complexing agents, such as amines and carboxylic acids, e.g. acetic acid and amino acids, are known and may be used in the formation of the multinuclear complexes of the invention. However since

many of the contrast enhancing multinuclear entities are extremely toxic it is clearly preferable that the formation constants of the multinuclear complexes should be as high as possible and accordingly it is particularly preferred that the multinuclear moiety should be bound in a chelate complex. Suitable chelant moieties will be discussed further below.


Many multinuclear complexes are known and attention is drawn for example to the following publications: Chisholm, *Trans. Met. Chem.* 3: 321 (1978); Lee et al., *Ang. Chem. Intl. Ed. Eng.* 29: 840-856 (1990); the Abstracts of the 5th International Conference on the Chemistry and Use of Molybdenum, 1985, page 133; Novák et al., *J. Inorg. Nucl. Chem.* 36: 1061-1065 (1974); Bürgi et al., *Inorg. Chem.* 20: 3829-3834 (1981); Chaudhuri et al., *Z. anorg. allg. Chem.* 521: 23-36 (1985); Ikari et al., *Inorg. Chem.* 29: 53-56 (1990); Tomohiro et al., *J. Chem. Soc. Dalton Trans.* 1990, 2459-2463; Henkel et al., *J. Chem. Soc. Dalton Trans.* 1990, 1014-1016; Barbaro et al. *JACS* 112: 7238-7246 (1990); Richens et al., *Inorg. Chem.* 28: 1394-1402 (1989); Saito et al., *Inorg. Chem.* 28: 3588-3592 (1989); *J. Chem. Soc. Dalton Trans* 1990, 1765-1769; *Inorg. Chem.* 27: 3626-3629 (1988); *JACS* 108: 2757-2758 (1986); and references cited therein. These multinuclear complexes generally fall into two categories, those in which the multinuclear moiety is bridged, that is to say where liganded metal atoms are bonded together via other atoms or ligands, and those where the moiety is unbridged, i.e. where the liganded metal atoms are bonded together directly. There is also a third general category in which the multinuclear moiety is apparently not bonded together, e.g. where two or more separate metal ions are complexed by the same chelant moiety.

Thus for example for the use of multinuclear complexes containing two liganded metal atoms (M) the main alternative structures are

7




and




where each M which may be the same or different is a metal atom; each L which may be the same or different is a ligand, either a molecule, an ion or one liganding moiety of a multidentate ligand; each B which may be the same or different is a bridging atom or ligand; and each m is an integer. Several L groups can of course be provided by one chelant and the metal atoms may be covalently bound to further atoms (generally designated by the letter A in the formulae referred to herein) not indicated by L or B and which function neither as ligands nor as bridges.

Where the M-B bonds to the bridging groups B of formula II are coordinate rather than covalent bonds, the multinuclear complex will be of the third general category referred to above. Examples of such complexes thus include the macrocyclic binuclear chelates such as



and






where each R which may be same or different is hydrogen or an organic group and each M which may be the same or different is a metal atom or ion, e.g. Ni, Pb(II) or Cu(II).

Where the liganded metal atoms are directly bonded, the MM distances tend to be short and the multinuclear complexes are generally diamagnetic. Several complexes falling into this category are well known, e.g. compounds of formulae




(where each M which may be the same or different is for example Mo or Re).

While the use of multinuclear complexes wherein the liganded atoms are bonded directly together or are not linked by covalent bonds does fall within the scope of the invention, it is particularly preferred that the multinuclear complexes be of the bridged type wherein the liganded metal atoms are covalently linked via bridging atoms. Many such complexes are known and typical exemplary structures include the bi-, tri-, tetra- and hexa- nuclear structures of formulae II, V, VIII and IX



10.



(IX)

where each m which may be the same or different is an integer, each B which may be the same or different is a bridging atom and each M which may be the same or different is a metal, e.g. Mo, W, Re, or Tc, and where other non-bridging atoms covalently bonded to metals M are omitted for the sake of clarity. These bi, tri, tetra and hexanuclear clusters of formula M_2B_2 , M_3B_4 , M_4B_4 , and M_6B_8 are well described in the literature, see for example

- J. Chem. Soc. A. 1970, 2421;
- JCS Dalton Trans. 1975, 1526-1530;
- Inorg. Chem. 16: 2538-2545 (1977);
- JACS 99: 4168-4169 (1977);
- J. Inorg. Nucl. Chem. 36: 1061-1065 (1974);
- Inorg. Chem. 28: 447-451 (1989);
- Chem. Letters, 1987, 2327-2330;
- J. Chem. Soc. Dalton Trans., 1987, 1163-1167;
- Inorg. Chem. 23: 4265-4269 (1984);
- Inorg. Chem. 24: 2950-2952 (1985);
- C.R. Seances Acad. Sci., Ser. C. 1966, 262, 1524;
- JACS 106: 2710-2711 (1984);
- J. Chem. Soc. Chem. Comm., 1985, 953;
- JACS 107: 5565 (1985);
- Inorg. Ch m. 27: 3626-3629 (1988);
- J. Chem. Soc. Dalton Trans., 1990, 1975-1769;
- JACS 108: 2757-2758 (1986);

JACS 106: 789-791 (1984);
 JACS 107: 6734-6735 (1985);
 Inorg. Chim. Acta 116: L25-L27 (1986);
 JACS 105: 3905-3913 (1983);
 J. Chem. Soc. Chem. Comm., 1990, 1014-1016;
 JACS 112: 7238-7246 (1990);
 JACS 110: 1646-1647 (1988);
 J. Chem. Soc. Dalton Trans., 1991, 51-59; and
 Inorg. Chem. 28: 3588-3592 (1989).

The complexes above may be electrically charged or neutral - for administration as contrast agents they are however preferably complexed with ligands/chelating agents which serve to improve water solubility and to reduce toxicity and to leave unaffected, to only slightly increase or, most preferably, to reduce the magnitude of the overall electronic charge carried by the complex.

In the case of bridged structures of these four formulae, the structural formulae can conveniently be written $M_2L_q(\mu_2B)_2$ and $M_3L_r(\mu_3B)(\mu_2B)_3$, $M_4L_s(\mu_3B)_4$ and $M_6L_t(\mu_3B)_8$ respectively (μ_3B indicating that the B is a bridging atom bonded to 3 metals, and q, r, s and t respectively being integers identifying the total number of complexing moieties). As mentioned above, it is particularly preferred that the multinuclear complexes be chelate complexes and it is especially preferred that a single multidentate chelant be used to coordinate at least two and preferably all of the liganded centres. A multidentate chelant L coordinating for example three metals would be referred to in these formulae as (μ_3L) .

Thus the multinuclear complexes used according to the invention preferably are compounds of the formula X




(where $M_nB_uA_v$ is a multinuclear entity; each M which

may be the same or different is a metal atom covalently bonded to at least one, preferably 2-4, atoms; each B which may be the same or different is a bridging atom covalently bonded to at least two, preferably 2 or 3, atoms M; each A which may be the same or different is a non-bridging atom covalently bonded to an atom M; each L which may be the same or different is a ligand, preferably a multidentate molecule or molecular ion, coordinately bonding to at least one atom M; n and u are positive integers of value 2 or greater; x and w are positive integers; and v is zero or a positive integer) or salts, especially physiologically tolerable salts, thereof.

In formula X above, n, u and v are preferably 2 to 30, especially 2 to 10, particularly 2 to 8; x is preferably 1 to 20, especially 1 to 10, and particularly 1. The value of w depends on the size and identity of the ligand - nonetheless w is preferably 1 or 2, especially 1.

Particularly preferred multinuclear complexes for use according to the invention include the APCA chelate complexes of mixed or non-mixed bi, tri, tetra and hexa nuclear oxides, sulphides, selenides and tellurides of molybdenum and/or tungsten, e.g. APCA chelates of multinuclear entities of formula




(VI)


(i.e. $M_3(\mu_3Z)(\mu_2Z)_3$)

13

(i.e.
 $M_4(\mu_3 Z)_4$)




(XI)



(XIII)

(i.e. $M_6(\mu_3 Z)_8$)

and more especially



(VII)

(i.e. $M_2Z_2(\mu_2 Z)_2$)

where each M is independently W or Mo and each Z is independently O, S, Se or Te, e.g.


$W_2S_2(\mu_2 S)_2$, $W_2O_2(\mu_2 O)(\mu_2 S)$, $W_2O_2(\mu_2 S)_2$, $MoWO_2(\mu_2 O)_2$,

$\text{Mo}_2\text{O}_2(\mu_2\text{O})_2$, $\text{Mo}_2\text{O}_2(\mu_2\text{S})_2$, $\text{W}_4(\mu_3\text{S})_4$, $\text{W}_3(\mu_3\text{S})(\mu_2\text{S})_3$,
 $\text{W}_3(\mu_3\text{Se})(\mu_2\text{Se})_3$, $\text{W}_3(\mu_3\text{Te})(\mu_2\text{Te})_3$, $\text{W}_4(\mu_3\text{Se})_4$, $\text{W}_4(\mu_3\text{Te})_4$,
 $\text{Mo}_3(\mu_3\text{Se})(\mu_2\text{Se})_3$, $\text{Mo}_4(\mu_3\text{Se})_4$, $\text{Mo}_2\text{O}_2(\mu_2\text{Se})_2$, $\text{Mo}_3(\mu_3\text{O})(\mu_3\text{O})_3$,
 $\text{W}_6(\mu_3\text{S})_8$, $\text{MoWO}_2(\mu_2\text{O})(\mu_2\text{S})$ and, particularly preferably,
 $\text{W}_2\text{O}_2(\mu_2\text{O})_2$.

Many of these multinuclear clusters are known from the literature cited above - the others may be prepared using methods analogous to those described in the literature.

Particularly conveniently, such multinuclear entities are presented as their chelate complexes containing EDTA or other APCA's. Such chelate complexes are remarkably stable with regard to release of the heavy metal ions and thus $\text{W}_2\text{O}_2(\mu_2\text{O})_2(\mu_2\text{EDTA})$, for example, has been found to have a stability constant in aqueous solution of about 29.1 (see Novák et al., J. Inorg. Nucl. Chem. 36: 1061-1065 (1974)).

The structure of the $\text{W}_2\text{O}_4\text{EDTA}^{2-}$, or more preferably $[\text{W(V)}_2\text{O}_2(\mu_2\text{O})_2(\mu_2\text{EDTA})]^{2-}$, multinuclear complex has been suggested by Novák (supra) and others to have the structure



Besides EDTA, other chelants are suitable for the preparation of the multinuclear chelate complexes used according to the invention.

It is particularly preferred that the electrical charge carried by the complexing moieties should

substantially if not completely balance that carried by the complexed entity; for APCA chelants this may easily be achieved for example by omission, replacement or deactivation (e.g. by ester or amide formation) of one or more of the carboxyl moieties.

Many suitable chelants are widely known or have been described in the literature, especially literature relating to heavy metal detoxification agents bifunctional chelants and chelate-based contrast agents, e.g. those described in WO-A-89/00557 (Berg) and the documents mentioned therein and in the search report appended thereto, US-A-4647447 (Gries), US-A-4826673 (Dean), EP-A-230893 (Felder), EP-A-217577 (Frincke), US-A-4652519 (Warshawsky), US-A-4687659 (Quay), and numerous other recent patent publications of Nycomed AS, Salutar Inc, Schering AG, Squibb, Bracco, Mallinckrodt, Dow and Guerbet.

The chelants useful for complexing the multinuclear moiety can be selected from a wide range of structures. Many of the most useful chelants are of general formula XIII



(where a is an integer of from 2 to 12, preferably 2 to 10, e.g. 2, 3, or 4; b is an integer of from 1 to 8, preferably 2, 3 or 4;


each R, independently is hydrogen, a hydrophilic or linking group (e.g. a hydroxyalkyl group) or two groups R₁, or one R₁ and one group Z', together represent a saturated or unsaturated heterocyclic or carbocyclic ring, preferably with 5-7 ring atoms;

each X independently is O, S, NZ' or PZ',

each Z' independently is hydrogen, hydroxyalkyl, mercaptoalkyl, carboxyalkyl (or an amide or ester derivative thereof e.g. -CH₂CONHCH₃) or optionally hydroxy or mercapto substituted acyl, or is a side chain

$((\text{CHR}_1)_a \text{X}^*)_c \text{Z}^*$ (where c is 1 to 4 and X^* and Z^* are as defined for X and Z' but do not represent any group containing a X^* or Z^* group) or two groups Z' together form a bridging group $((\text{CHR}_1)_a \text{X}^*)_c (\text{CHR}_1)_a$ or are salts thereof.

While polyamines, especially linear or cyclic polyamines, such as ethylenediamine, 1,4,7-triazacyclononane and cyclen, can be used as chelants, in general APCAs are preferred, particularly DTPA, EDTA and derivatives thereof and other cyclic and non-cyclic APCAs as defined in WO-A-89/00557 and APCAs of formula XIV



where each R_1 is independently hydrogen or an optionally hydroxylated and/or alkoxyated alkyl group or an organic side chain adapted for the attachment of or attached to a macromolecule;

d and e each is an integer having a value of 1, 2 or 3; each X is independently a group COOH or a derivative thereof;

each Y is independently a group X , SR_1 , OR_1 or $\text{N}(\text{R}_3)_2$;

E is a group $(\text{CHR}_2)_f (\text{X}''(\text{CHR}_2)_f)_g$

where f is an integer of from 2 to 5, preferably 2 or 3, g is zero, 1 or 2, preferably zero or 1, each f preferably being 2 when g is non-zero,

X'' is O , S or $\text{N}(\text{CHR}_1)_d \text{Y}$, preferably O or S ,



each R_2 is independently R_1 or, when the carbon to which it is attached is not bonded to a nitrogen, hydroxyl, or two R_2 groups, especially where f is 2, may together with the intervening carbons form a cycloalkyl group

optionally substituted by hydroxyl or R_1 groups, and each R_3 is independently a group R_1 or $\text{N}(\text{R}_3)_2$ represents a preferably saturated heterocyclic group preferably


having 5 or 6 ring members, optionally containing as a further heteroatom a nitrogen or oxygen and optionally substituted by R₁ groups.







In the chelants of formula XIII or XIV, any alkyl moiety preferably has a carbon atom content of up to 8, any cycloalkyl group preferably is a C₃₋₈, especially C₅₋₇, ring and any carboxyl derivative is preferably a CON(R₃)₂ or CON(OH)R₁ group.

Examples of suitable chelants include compounds of formulae:




(where $y = 6, 7, 8, 9$ or 10
and $z = 0$ or 1)








(xvi)



(xvii)



(xviii)



and the phosphorus analogues of these nitrogen-donor based ligands.

For M_4B_4 multinuclear complexes, e.g. $W_4(\mu_3B)_4^{4+}$ (where $B = S, Se, Te, O, N-R^{31}$ or $P-R^{31}$ (where R^{31} is an appropriate substituent, e.g. hydrogen, aryl (e.g. phenyl), alkyl etc.)), chelants (i) to (vii) (where $z = 1$) are of particular interest; for M_3B_4 complexes, e.g. $W_3(\mu_3B')(\mu_2B'')_3^{4+}$ (where B' and B'' are S, Se, Te, O, NR^{31} or PR^{31} , B' preferably being S), chelants (vii) (where $z = 0$) and (viii) to (xv) are of particular interest; and for M_6B_8 complexes, e.g. $W_6(\mu_3S)_8$, chelants such as (xvi) to (xx) are of particular interest. For M_2B_2 complexes, e.g. $W_2O_2(\mu_2O)_2^{2+}$ chelants such as NTA, IDA, EDTA, HEDTA, DTPA, DTPA-BMA, HEDDA, TTDA, EDTA-BMA, TBEDDA, MEEDDA, TTHA, EDDA, EHPG, PDTA, CHDTA, HPDTA and triazacyclononane monoacetic acid, especially PDTA and EDTA, are of particular interest.


For M_4B_4 and M_3B_4 multinuclear complexes, the use of macrocyclic chelants, e.g. those of formula (vii) is particularly preferred as a means by which to enhance solution stability.

Particularly preferred chelants include cyclen, EDTA, DTPA, DOTA, DO3A, HP-DO3A, the 6-oxa and 6-thia analogues of DTPA and amides thereof, e.g. DTPA-BMA and DTPA-BMO (6-carboxymethyl-3,9-bis(morpholinocarbonylmethyl)-3,6,9-triazaundecanedioic acid - the Gd(III) chelate whereof is sometimes referred to as gadopenamide).





Where the chelant is to be attached to a macromolecule, this may conveniently be any tissue, organ or cell targeting macromolecule, for example a biomolecule such as a protein, an antibody or antibody fragment, or alternatively it may be a biologically relatively inert material such as a polysaccharide or poly-sugar alcohol, e.g. dextran or starch. Such macromolecules are discussed extensively in the recent literature relating to contrast agents.

The chelants of formulae XIII and XIV are already known from the literature or may be prepared in analogous fashion to the known chelants. The preparation of chelants of formula XIII and XIV will however generally fall into one of two categories: derivatization of a polyamine or amination of polyfunctional compounds. Derivatization can be performed in one or more stages and the groups introduced may, in intermediate or final stages, be subject to reduction or deprotection steps.

Thus for example starting from the linear polyamine




(where E' is $(CHR_2)_f[X''(CHR_2)_g]$, and X'' is O, S or NH) derivatization may be effected by the following nonreductive or reductive reaction schemes:





where L is a leaving group and R'_1 , Y' and X' are optionally protected R_1 , Y and X groups.

Alternatively a bifunctional reagent of formulae



may be aminated with or without a subsequent reduction step according to the following schemes:





where E'' is $(\text{CHR}'_1)_{f-h}[\text{Z}'(\text{CHR}'_1)_f]_i[\text{Z}'(\text{CHR}'_1)_{f-1}]_j$ (where j is 0 or 1, $h+j$ is 2, i is zero or the positive integer $g-1$) and L, R'_1 , Y' and X' are as hereinbefore defined.

The polyamine starting materials are either available commercially or may be prepared by routine methods. Thus for example commercially suitable polyamines include $\text{NH}_2(\text{CH}_2)_{2-5}\text{NH}_2$, $\text{NH}_2(\text{CH}_2)_2\text{O}(\text{CH}_2)_2\text{NH}_2$, $\text{NH}_2\text{CH}_2\text{CHOHCH}_2\text{NH}_2$, $\text{NH}_2(\text{CH})_2\text{S}(\text{CH}_2)_2\text{NH}_2$. Optionally substituted polyamines may also be prepared by methods described in or analogous to those of EP-A-287465 (Schaeffer), WO-A-89/00557 (Berg), Brechbiel et al. Inorg. Chem. 25: 2772 (1986), Yeh et al. Analytical Biochem. 100: 152 (1979), Vögtle et al. Liebigs Ann. Chem. (1977) 1344, Kasina et al. J. Med. Chem. 29: 1933 (1986), Bedell et al. Inorg. Chem. 21:874 (1982), etc.


Derivatization of the polyamines may be effected using alkylation agents such as those described by EP-A-230893 (Felder), e.g. $\text{HalCH}_2\text{COL}''$, $\text{HalCH}(\text{COOH})\text{CH}_2\text{O}$ Benzyl, or $\text{HalCH}(\text{COOH})_2$ (where Hal is Cl or Br and L'' is OH, NHalkyl or Nalkyl_2 (e.g. NHCH_3 or $\text{N}(\text{CH}_3)_2$) or $\text{HalCH}_2\text{Nalkyl}_2$ (e.g. $\text{ClCH}_2\text{N}(\text{CH}_3)_2$), followed where necessary by deprotection of protected groups. Examples of such schemes include

22




Selective alkylation of amines is described by Nordlander et al. Tetr. Lett. (1978) 4987 and J. Org. Chem. 49: 133 (1984) and by Aspinall et al. JACS 63: 852 (1941). Many other appropriate derivatization procedures are described in the literature.

For the reductive procedure discussed above, reaction may be of many of the same or similar polyamines with aldehyde, carboxyl or carboxyl derivative compounds followed by reduction of the amide carbonyl groups, e.g. using sodium cyanoborohydride or diborane, e.g. as in the scheme




(XIV)

The resulting thioesters could equally be produced by reaction of an aminocarboxylic acid reagent with a chloroalkylsulphide, e.g.



As mentioned above, the chelants of formula (XIV) can also be produced by amination of polyfunctional reagents. One example of this procedure is given by Huber et al. J. Chem. Soc. Chem. Comm. (1989) 879, i.e.




The resulting polyamine can then be converted to a compound of formula XIV by reaction with HOCH_2CN followed by hydrolysis. A wide variety of other polyhalo and amine compounds suitable for use in such reactions are available commercially or may be prepared using text book methods.

In a similar manner, polyfunctional acids may be reacted with appropriate amines if necessary after activation of the acid groups, reduction of the amide and alkylation will yield chelants of formula XIV. Commercially available polyfunctional acids utilizable in this way include for example




where B is $-\text{CHOHCH}_2\text{CH}_2-$, $-(\text{CHOH})_2-$,
 $-(\text{CH}_2)_{1-3}-$ or




In order to attach the chelant to a macromolecule, e.g. a protein or a carbohydrate, the chelant may be provided with a reactive side chain (e.g. described by Meares et al. Anal. Biochem. 142: 68(1984), etc). Alternatively attachment can be effected for example using the methods developed by Salutar Inc. (See for example WO-A-90/12050 and Sieving et al., Bioconjugate Chem. 1: 65-71 (1990)) or the mixed anhydride or cyclic anhydride methods of Krejcarek et al Biochemical and Biophysical Research Comm. 77: 881 (1977) or Hnatowich et al. Science 220: 613 (1983) etc. Attachment of the chelant may be either directly to the macromolecule or, preferably, to a an intermediate polymer, e.g. poly-L-lysine or polyethylene-imine, onto which a plurality of chelants may be loaded, e.g. as discussed in EP-A-331616 (Deutsch).


Thus for example the following macromolecule-linkable chelants are suggested in the literature:




(Westerberg et al. J.
Med. Chem. 32: 736
(1989))
(Ac=CH₂COOH)



(JACS 59: S+D 10
(1982))




(Turowski et al.
Inorg. Chem. 27: 474
(1988))




(Hernandez et al. An.
Quim. Ser. B. 83: 172
(1987))

26




(Zupanc et al. Glas.
Hem Technol. Bosne
Hercegovine (1970)71)


(R⁺ - NO₂, OH)




(EP-A-217577 (Frinke))



(J. Radiol. Chem. 53:
327 (1979))



(Bulman et al. Inorg.
Chem. 26: 2483 (1987))



(US-A-4632519

(Warshawsky))

(R* = COOH, NH₂, CHO)

The tridentate tris-thiols of Holm et al. (see JACS 112: 8015-8023 (1990) and JACS 110: 2484-2494 (1988)) also deserve particular mention, especially for the complexation of tetranuclear clusters.

The multinuclear complexes used according to the invention may be prepared by the methods suggested in the literature or by analogous methods. In particular, novel complexes may be prepared from known complexes by ligand interchange.




Thus, for example for tungsten based multinuclear entities as mentioned above, oxalatotungstate(V) may be used as a starting material and ligand exchange reactions with calcium chelates of APCAs to precipitate out calcium oxalate may be carried out. Chromatographic isolation and purification methods, such as suggested by Ikari (supra) appear particularly suitable.

The preparation of an intermediate oxalate may be avoided by use of other literature known methods, e.g. the electrochemical reduction suggested by Baba et al. Mem. Fac. Tech. Tokyo Metropolitan Univ. 32: 3207 (1982).

Other preparative techniques that deserve particular mention include the oxidation of tungstate complexes with the addition of the desired chelant/complexant as suggested by Chaudhuri (supra) and the reduction of tungstates with reductants and a chelant/complexant (which may have oxidative or reductive properties) as suggested by Lozano et al. in Polyhedron 31: 25-29 (1984).







Further examples of synthetic routes by which the

multinuclear complexes used according to the invention may be prepared include:




(XXIV)

(where $\text{X}_1 = \text{N}$ or P
and $\text{Z}' = \text{H}$ or alkyl)




+






(XX)


29



(where $X_1 = \text{N or P}$
 $X_2 = \text{O or S}$
 and $Z' = \text{H or alkyl}$)



(where X_1 , X_2 and Z'
 are as in (A) above)






(XXIII)





Molybdenum and tungsten trinuclear aqua complexes

$[\text{M}_3(\mu_3\text{B})(\mu_2\text{B})_3(\text{H}_2\text{O})_9]^{4+}$ (where M is Mo or W and B is O or S) can be prepared by methods known from the literature.

The co-ordinated waters in these complexes can readily be replaced by chelants xvi to xx to reduce toxicity. Single or mixed ligand combinations may be used to produce ionic or non-ionic complexes.






(where X_1 and Z' are as in (A) above)






(where Z' , X_1 and X_2 are as in (A) above)

31





$$\xrightarrow{\quad}$$

$$\text{R}^{32} = \text{H, alkyl, phenyl, etc.}$$








$$(k = 6 \text{ to } 10)$$

The coordinated water in the tetranuclear aqua complexes may be substituted by ligands such as chelants i to vii to reduce toxicity. Selected examples are shown below.



(XXI)

32



Molybdenum and tungsten based tetranuclear aqua complexes $(M_4(\mu_3B)_4(H_2O)_{12})^{n+}$ (where M = W or Mo, B = S or Se and n = 4 or 5) can be prepared by various chemical and electrochemical procedures. Tetranuclear tungsten complexes may also be prepared by reduction of binuclear complexes, e.g. using reductants such as $NaBH_4$, $Na_2S_2O_4$ and Zn/Hg amalgam and the compound of formula XXIV, by photoirradiation of tungsten hexacarbonyl and sodium sulphide in methanol, or of a mixture of a trinuclear

complex and tungsten hexacarbonyl in methanol or reaction of a trinuclear complex and the W(III) aquoion under reducing conditions with heat or photo-irradiation.

For administration to human or animal subjects, the multinuclear complexes will conveniently be formulated together with pharmaceutical or veterinary carriers or excipient. The contrast media of the invention may conveniently contain pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, colorants, flavours, viscosity adjusting agents and the like. They may be in forms suitable for parenteral or enteral administration, for example, injection or infusion or administration directly into a body cavity having an external voidance duct, for example the gastrointestinal tract, the bladder and the uterus. Thus the media of the invention may be in conventional pharmaceutical administration forms such as tablets, coated tablets, capsules, powders, solutions, suspensions, dispersions, syrups, suppositories etc; solutions, suspensions and dispersions in physiologically acceptable carrier media, e.g. water for injections, will however generally be preferred. Where the medium is formulated for parenteral administration, the carrier medium incorporating the multinuclear complex is preferably isotonic or somewhat hypertonic. Moreover, media for parenteral administration will preferably contain small quantities, e.g. 0.01 to 10 mole percent relative to the multinuclear complex of free chelants or of weak chelate complexes with physiologically tolerable chelated species (e.g. Ca^{2+}); small additions of sodium or calcium salts may also advantageously be made.

For use as X-ray contrast media, the media of the invention should generally have a heavy atom content of 1 millimole/l to 5 mole/l, preferably 0.1 to 2 mole/l. Dosages of from 0.5 to 1.5 mmoles/kg will generally be

sufficient to provide adequate contrast although dosages of 0.8 to 1.2 mmoles/kg will normally be preferred.

For scintigraphy, dosages of the radioactive species will generally be lower.

Thus in summary the present invention provides a particularly effective means by which contrast media efficiency may be enhanced by increasing the relative proportion of molecular volume that is occupied by the contrast enhancing heavy or paramagnetic metal atom. For X-ray contrast media in particular, this also enables higher K- edge value atoms than the iodine of the now conventional X-ray contrast media to be utilized

~~effectively.~~

The present invention will now be illustrated further by the following non-limiting Examples (all ratios and percentages are by weight and all temperatures are in degrees Celsius unless specified otherwise):

Example 1

Bis(μ -oxo)(μ -ethylenediaminetetraaceto-N,N')bis-(oxotungstate(V)), disodium salt $\text{Na}_2[\text{W}_2\text{O}_2(\mu_2\text{O})_2(\mu_2\text{EDTA})]$

Alternative A:

The potassium salt (37 g, 65 mmol) of the oxalato complex of tungsten(V) (prepared according to Collenberg, Z. Anorg. Allg. Chem. 102: 247-276 (1918)), sodium acetate (60 g, 441 mmol) and ethylenediaminetetraacetic acid (10 g, 34 mmol) were dissolved in oxygen free water (800 ml) and warmed to 80-90 °C under nitrogen. Degassed warm calcium acetate solution (1M, 150 ml) was added with stirring and the mixture was allowed to cool. After filtering off the precipitate, degassed barium acetate solution (1M, 40 ml) was added. A small amount of the immediate precipitate was filtered off and the filtrate was concentrated in vacuo. The residue was collected on a filter, washed with water and dried.

This material (18.1 g, 21 mmol barium-complex) was dissolved in warm oxygen free water (2000 ml) and sodium sulfate solution (1M, 25 ml) was added. The mixture was allowed to cool, filtered and concentrated to dryness. The residue was taken up with water (50 ml) and precipitated by successive addition of ethanol.

Yield: 15.17 g (30 %) of the sodium salt of tungsten-EDTA complex.

Purification of 10 g by HPLC afforded the title compounds of Example 1 (3g) and Example 2 (4.25g)

¹H-NMR was as reported by Ikari et al., Inorg. Chem. 28: 1248-1254 (1989).

Alternative B:

The potassium salt (0.10 g, 0.062 mmol) of the oxalato complex of tungsten(V) (prepared according to Baba et al., Mem. Fac. Tech. Tokyo Metropolitan Univ. 32: 3207-3220 (1982)), ethylenediaminetetraacetic acid (0.028 g, 0.124 mmol) and sodium acetate (0.021 g, 0.25 mmol) were dissolved under nitrogen in oxygen free water (1.5 ml) and heated to 100 °C. Calcium chloride dihydrate (0.046 g, 0.31 mmol) dissolved in oxygen free water (2 ml) was added and the mixture allowed to cool. After filtering off the precipitate, barium hydroxide (0.043 g, 0.136 mmol), dissolved in water (2 ml), at pH 4 (acetic acid) was added. The mixture was concentrated in vacuo to near dryness, the precipitate collected by centrifugation, washed with two drops of water and dried in vacuo over P₂O₅.

Yield : 0.044 g (21 %) of the barium salt of the complex.

This was dissolved in water (20 ml) with heating, sodium sulfate (0.017 g, 0.05 mmol) dissolved in water (2 ml) was added and the precipitate removed by centrifugation. Concentration of the clear solution to dryness gave the title compound quantitatively. HPLC-analysis showed the product to be identical with that prepared by alternative A.

Example 2

(μ-Ethylenediaminetetraaceto-N,N')(μ-oxo)(μ-sulphido)bis(oxotungstate(V)), disodium salt
Na₂[W₂O₂(μ₂O)(μ₂S)(μ₂EDTA)]

The potassium salt (37 g, 65 mmol) of the oxalato complex of tungsten(V) (prepared according to Collenberg, Z. Anorg. Allg. Chem. 102: 247-276 (1918)), sodium acetate (60 g, 441 mmol) and

ethylenediaminetetraacetic acid (10 g, 34 mmol) were dissolved in oxygen free water (800 ml) and warmed to 80-90 °C under nitrogen. Degassed warm 1M calcium acetate solution (150 ml) was added with stirring and the mixture was allowed to cool. After filtering off the precipitate, degassed 1M barium acetate solution (40 ml) was added. A small amount of immediate precipitate was filtered off and the filtrate was concentrated in vacuo. The residue was collected on a filter, washed with water and dried.

This material (18.1 g, 21 mmol barium - complex) was dissolved in warm oxygen free water (2000 ml) and 1M sodium sulfate solution (25 ml) was added. The mixture was allowed to cool, filtered and concentrated to dryness. The residue was taken up with water (50 ml) and precipitated by successive addition of ethanol.

Yield 15.17 g (30 %) of the sodium salt of tungsten-EDTA complex.

Purification of 10 g crude material by HPLC afforded 4.25 g of the title compound.

¹H-NMR was as reported by Ikari et al., Inorg. Chem. 28: 447-451 (1989).

Example 3

Bis(μ -sulphido)(μ -ethylenediaminetetraacetato-N,N')bis(oxotungstate(V)), disodium salt
 $\text{Na}_2[\text{W}_2\text{O}_7(\mu_2\text{S})_2(\mu_2\text{EDTA})]$

Alternative A

The title compound is prepared and purified according to the procedure of Shibahara et al., 37th Nat. Conf. Coord. Chem., Tokyo, Abstr. 1AP06.

Alternative B

1g of $(\text{NH}_4)_2\text{WS}_4$ (2.87 mmol) was dissolved in 20 ml of H_2O to give a yellow suspension. 1g of NaBH_4 on alumina and

10 ml of 6 M HCl were alternatively added to the yellow suspension. An immediate dark-brown suspension was formed, which was then heated at 120°C under an O₂ stream for 15 hours. After cooling the resulting mixture to ambient temperature, a green solid was removed by filtration. The red-brown filtrate was treated with 0.6g of Na₄EDTA. After the pH of the mixture was adjusted to 1.2, it was heated at 100°C for 1 hour. Some precipitate was observed during this heating period. After removing the solid by filtration, the yellow-orange filtrate was cooled and left at ambient temperature for 4 days, giving orange crystals. The crystals were washed with a small amount of methanol and then dried in the air. The yield was 0.20g.

The mass spectral data of this product showed the molecular ions at 791 and 753 corresponding to the mass of K[W₂O₂S₂(EDTA)] and [W₂O₂S₂(EDTA)] + H, respectively. ¹H NMR resonances in D₂O were found at 2.54 ppm(s, 4H), 3.14 ppm(d, 2H, J = 16.4 Hz), 3.40 ppm(d, 2H, J = 17.1 Hz) and 3.52 ppm(d, 4H J = 17.1 Hz).

Example 4

Bis(μ-oxo)(μ-ethylenediaminetetraaceto-
N,N')(oxomolybdenum(V)) (oxotungstate(V)), disodium salt
Na₂[MoWO₂(μ₂O)₂(μ₂EDTA)]

The title compound is prepared and purified according to the procedure of Ikari et al. Inorg. Chem. 28: 1248-1254 (1989).

Example 5

Preparation of a solution containing the disodium salt
of bis(μ-oxo)(μ-ethylenediaminetetraaceto-
N,N')bis(oxotungstate(V))

The salt from Example 1 (2.95 g, 3.85 mmol) was dissolved in water (18 ml) and the pH was adjusted to 7 by careful addition of 1 M sodium hydroxide. Water was added to 20 ml, the solution passed through a 0.22 μm sterile filter and placed into four 5 ml vials.

The solution contained 0.20 mmol of the disodium salt of bis(μ -oxo)(μ -ethylenediaminetetraaceto-N,N')bis(oxotungstate(V)) per ml.

The LD₅₀ in mice was found to be 10-14 mmol/kg.

Example 6

Preparation of a solution containing the disodium salt of (μ -ethylenediaminetetraaceto-N,N')(μ -oxo)(μ -sulphido)bis(oxotungstate(V))

The salt from Example 2 (2.66 g, 3.40 mmol) was dissolved in water (17 ml) and the pH was adjusted to 7.0 by careful addition of 1 M sodium hydroxide. The solution was passed through a 0.45 μm filter into four 5 ml vials.

The solution contained 0.19 mmol of the disodium salt of (μ -ethylenediaminetetraaceto-N,N')(μ -oxo)(μ -sulphido)bis(oxotungstate(V)) per ml.

The LD₅₀ in mice was found to be approx. 10 mmol/kg.

Example 7

Preparation of a solution containing the disodium salt of bis(μ -sulphido)(μ -ethylenediaminetetraaceto-N,N')bis(oxotungstate(V))

The salt from Example 3 (2.00 g, 2.5 mmol) is dissolved in water (12.5 ml) and the pH is adjusted to 7.0 by careful addition of 1 M sodium hydroxide. The solution is filtered into three 5 ml vials.

Example 8

Preparation of a solution containing the disodium salt of bis(μ -oxo)(μ -ethylenediaminetetraaceto-N,N')(oxomolybdenum(V)) (oxotungstate(V))

The salt from Example 4 (2.00 g, 2.95 mmol) is dissolved in water (14.7 ml) and the pH is adjusted to 7.0 by careful addition of 1 M sodium hydroxide. The solution is filtered into three 5 ml vials.

Example 9

Bis(μ -oxo)(μ -N,N'-propylenediaminetetraacetato)bis(oxotungstate(V)), barium salt $\text{Ba}[\text{W}_2\text{O}_2(\mu_2\text{O})_2(\mu_2\text{PDTA})]$

The potassium salt (1.61 g, 1 mmol) of the oxalato complex of tungsten(V) (prepared according to Baba et al., Mem. Fac. Tech. Tokyo Metropolitan Univ. 32: 3207-3220 (1982)) and 1,2-diaminopropane-N,N,N',N'-tetraacetic acid (0.612 g, 2 mmol) were dissolved under nitrogen in a mixture of 50 ml oxygen-free water and sodium acetate-solution (1M, 8 ml) and heated to 100°C. Calcium acetate-solution (1M, 10 ml) was added with stirring and the mixture allowed to cool. After filtering off the precipitate, a barium acetate-solution (1M, 2 ml) was added, the solution was filtered and the title compound was precipitated by dropwise addition of ethanol. It was collected on a filter, washed with 50% aqueous methanol and dried in vacuo at 40°C. Yield: 0.413 g (43%) of the pentahydrate.

Example 10

Bis(μ -oxo)(μ -N,N'-propylenediaminetetraacetato)bis(oxotungstate(V)),

sodium salt $\text{Na}[\text{W}_2\text{O}_2(\mu_2\text{O})_2(\mu_2\text{PDTA})]$

The title compound is prepared by dissolving the barium salt of Example 9 in warm water. After addition of a stoichiometric amount of a 1M sodium sulfate solution the mixture is allowed to cool, filtered and the filtrate concentrated to dryness.

Example 11

$[\text{W}_3(\mu_3\text{-S})(\mu_2\text{-S})_3(\text{H}_2\text{O})_9]\text{Cl}_4$

The title compound was prepared by a slightly modified version of the procedure described in JACS 108:2757-2758 (1986).

3 g of $(\text{NH}_4)_2\text{WS}_4$ (8.62 mmol) was dissolved in 75 ml of water to give a yellow solution. 3 g of NaBH_4 and 30 ml of concentrated HCl were added alternatively to the tungsten solution. Upon this addition, an immediate color change from yellow to dark brown was observed. The resulting brown suspension was heated at 100°C for 2 hours. After cooling the mixture, it was filtered to remove a dark brown solid and to obtain a brown filtrate. The brown solution was loaded on a Sephadex G-15 column, which resulted in a brown band on top of the column. After a 5-day air oxidation of the brown band, it was eluted with 2 M HCl solution. The second purple fraction ($\lambda_{\text{max}} = 570 \text{ nm}$ and 320 nm) was collected and evaporated to dryness under high vacuum at $36\text{-}40^\circ\text{C}$, which gave dark grey solid. The product was washed with acetone and dried in the air. The yield was 0.506 g (0.62 mmol, 22%).


The mass spectral data in dithiothrietol (DTT)/dithioerythrietol matrix gives a molecular ion at 1139 equivalent to the mass of $[\text{W}_3\text{S}_4(\text{DTT})_3] + 2\text{H}$.

The elemental analysis indicated that the product was $\text{W}_3\text{S}_4(\text{H}_2\text{O})_9\text{Cl}_4$ and contained 2.4% HCl and 3.9% H_2O .

Calculated: W(52.53%), S(12.22%), Cl(15.86%).

Found: W(52.46%), S(12.24%), Cl(15.96%).

Example 12



This compound was prepared according to a literature procedure. (Inorg. Chem. 23: 4265-4269 (1984)). 0.81g (2.3 mmol) of $(NH_4)_2WS_4$ was added to 25 ml of N_2 -saturated DMF. The resulting mixture was a greenish-yellow suspension. After adding 0.3 ml (3.6 mmol) of 1,2-ethanedithiol (EDT), a bright yellow color formed. The reaction mixture was heated under a N_2 flow at $120^\circ C$ in an oil bath for 2 hours. After several minutes of heating, the solution became red-orange. At the end of the reaction period, a brownish red suspension was noted, 0.63g of $N(C_2H_5)_4Cl$ was then added to the cooled suspension at ambient temperature. 20 ml of diethyl ether was added to precipitate the product. Brownish red crystals were recovered by filtration and washed with methanol and then with ether. The addition of more ether (150 ml) to the red-orange filtrate gave more product. All the fractions were then combined and recrystallized once from methanol. The total yield of the product was 0.75g (1.6 mmol, 69% from $(NH_4)_2[WS_4]$).

The mass spectral data of this product showed a molecular ion at 681 corresponding to $W_2S_4(EDT)_2 + H$.

Claims

1. A diagnostic imaging contrast medium comprising a physiologically tolerable multinuclear complex comprising at least two contrast enhancing atoms together with at least one pharmaceutical carrier or excipient.

2. A medium as claimed in claim 1 wherein said multinuclear complex comprises at least two contrast enhancing metal atoms bonded together via covalently bonded non-metal bridging atoms.

3. A medium as claimed in either of claims 1 and 2 wherein said multinuclear complex comprises at least two contrast enhancing metal atoms coordinately bound by a ligand.

4. A medium as claimed in any one of claims 1 to 3 wherein said multinuclear complex is of formula



(where $M_n B_u A_v$ is a multinuclear entity; each M which may be the same or different is a contrast enhancing metal atom covalently bonded to at least one atom B; each B which may be the same or different is a bridging atom covalently bonded to at least two metal atoms M; each A which may be the same or different is a non-bridging atom covalently bonded to an atom M; each L which may be the same or different is a ligand coordinately bonded to at least one metal atom M; n and u are positive integers of value 2 or greater; x and w are positive integers; and v is zero or a positive integer)

or is a physiologically tolerable salt thereof.

5. A medium as claimed in claim 4 where each M is W or Mo, each A and B is O, S, Se, Te or a protonated or substituted nitrogen or phosphorus atom and n is 2-6.
6. A medium as claimed in claim 5 wherein the multinuclear entity is of formula $M_2(\mu_2B)_2B_2$ where each B is O or S and each M is W or Mo.
7. A medium as claimed in claim 5 wherein the multinuclear entity comprises a unit of formula
 $M_3(\mu_3B)(\mu_2B)_3$
 $M_4(\mu_3B)_4$
 $M_6(\mu_3B)_8$
 where each M is W or Mo and each B is O, S, Se, Te or a protonated or substituted nitrogen or phosphorus atom.
8. A medium as claimed in any one of claims 1 to 7 wherein said multinuclear complex is a complex with a polyamine chelant.
9. A medium as claimed in claim 8 wherein said chelant is an aminopolycarboxylic acid or an ester or amide thereof or is a macrocyclic polyacylated-polyamine.
10. A medium as claimed in any one of claims 1 to 9 further comprising a free chelant or a physiologically tolerable salt or a weak complex thereof with a physiologically tolerable metal ion.
11. Multinuclear complexes for use in diagnosis.
12. Complexes as claimed in claim 11 of tungsten and/or molybdenum
13. The use of multinuclear complexes for the manufacture of a contrast medium for use in imaging of humans or non-human animals.

14. A method of generating an image of a human or non-human animal body which method comprises administering to said body a physiologically tolerable multinuclear complex and generating an image of at least part of said body.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁴

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: A 61 K 49/04, 49/00**II. FIELDS SEARCHED**Minimum Documentation Searched ⁷

Classification System

Classification Symbols

IPC⁵

A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹**

Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO, A, 8910372 (CENTRE NAT. DE LA RECHERCHE SCIENTIFIQUE) 2 November 1989, see page 24, claims	1-13
Y	FR, A, 2348699 (F. HOFFMAN LA ROCHE & CIE.) 18 November 1977, see claim 1	1-13
Y	J. Inorg. Nucl. Chem., vol. 36, 1974, Pergamon Press, (Oxford, GB) J. Novák et al.: "Tungsten(V) complexes of ethylenediaminetetra- acetic acid", pages 1061-1065 see the abstract (cited in the application)	1-6, 8-13
Y	J. Am. Chem. Soc., vol. 110, 1988, American Chem. Soc. (Washington, DC, US) T. Saito et al.: "Synthesis of [Mo ₆ S ₈ (PEt ₃) ₆] by reductive dimerization of a trinuclear molybdenum chloro sulfido cluster complex coordinated with triethylphosphine and methanol:	1-5, 7-13

¹⁰ Special categories of cited documents:^{"A"} document defining the general state of the art which is not considered to be of particular relevance^{"E"} earlier document but published on or after the international filing date^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^{"O"} document referring to an oral disclosure, use, exhibition or other means^{"P"} document published prior to the international filing date but later than the priority date claimed^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"Δ"} document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

15th July 1991

Date of Mailing of this International Search Report

- 9. 09. 91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. PEIS

M. Peis

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	<p>a molecular model for superconducting Chevrel phases", pages 1646-1647 see the whole article (cited in the application)</p> <p>--</p>	
Y	<p>J. Am. Chem. Soc., vol. 108, 1986 American Chem. Soc. (Washington, DC, US) T. Shibahara et al.: "Preparation of triangular tungsten (IV) aqua ion, $W_3S_4^{4+}$ and X-ray structure of $(bpyH)_5 [W_3S_4(NCS)_9] \cdot 3H_2O$", pages 2757-2758 see the whole article (cited in the application)</p> <p>--</p>	1-5,7-13
Y	<p>Inorganic Chem. vol. 16, no. 10, 1977 (Washington, DC; US) V.R. Ott et al.: "Di-μ-oxo, μ-oxo-μ-sulfido, and di-μ-sulfido complexes of molybdenum (V) with EDTA, cysteine, and cysteine ester ligands. Preparation and electrochemical and spectral properties", pages 2538-2545 see the whole article (cited in the application)</p> <p>-----</p>	1-6,8-13

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers 14 because they relate to subject matter not required to be searched by this Authority, namely:
See PCT-Rule 39.1(iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods
2. ☒ Claim numbers incompletely: 1-13 because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:
The term "multinuclear complex" used in the claims is not sufficiently
3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9100587

SA 45872

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 04/09/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8910372	02-11-89	FR-A- 2630547	27-10-89
		EP-A- 0412104	13-02-91

FR-A- 2348699	18-11-77	US-A- 4079124	14-03-78
		DE-A- 2717819	03-11-77
		JP-A- 52130927	02-11-77
		NL-A- 7704363	25-10-77

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82